pharma · Locally advanced or metastatic urothelial cancer · Nectin-4 Expressing Advanced Malignancies. · BCYC
BICYCLE THERAPEUTICS
BICYCLE THERAPEUTICS clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Cambridge, GB
- Founded
- 2009
- Employees
- 282
- Programs
- 8
- Drugs
- 15
- Patents
- 57
BICYCLE THERAPEUTICS projects
5 ClinicalTrials.gov programs sponsored by BICYCLE THERAPEUTICS.
BICYCLE THERAPEUTICS has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BT1718
BICYCLE THERAPEUTICS
Advanced Solid Tumours
1 trial -
BT8009, Zelenectide Pevedotin
BICYCLE THERAPEUTICS
NECTIN4 Amplified Advanced Breast Cancer
1 trial -
BT8009-100
BICYCLE THERAPEUTICS
Nectin-4 Expressing Advanced Malignancies.
1 trial -
NIVOLUMAB, BT5528
BICYCLE THERAPEUTICS
Advanced Malignancies Associated with EphA2 Expression
1 trial -
Zelenectide Pevedotin, BT8009
BICYCLE THERAPEUTICS
Advanced or Metastatic Non-small Cell Lung Cancer
1 trial
Frequently asked questions
How many clinical projects does BICYCLE THERAPEUTICS have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.